Medical sector’s Corbus Pharmaceuticals (NASDAQ:CRBP)’s Buy rating Reiterated by Oppenheimer Holdings Inc.

0
33
stock_market_daily_information
Business or finance concept : Asia Pacific stock market data and candle stick graph chart on monitor

Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its Buy rating Reiterated by analysts at Oppenheimer Holdings Inc. in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 608.2M and a beta of 1.45.  Corbus Pharmaceuticals has a twelve month low $3.29 of  and a twelve month high of $8.66.

Shares of Corbus Pharmaceuticals traded up $0.48 on Tuesday, reaching $8.39. 2614028 shares of the stock traded hands, compared to its average volume of 1666704. Shares of Corbus Pharmaceuticals at end of the day on Tuesday were at $8.39. The firm’s 50 day moving average is $7.01 and its 200 day moving average is 5.72.Corbus Pharmaceuticals  has a 12 month low of $7.95 and a 12 month high of $8.66. While on yearly highs and lows, Corbus Pharmaceuticals’s today has traded high as $8.56 and has touched $7.95 on the downward trend. See More Analyst Rating at: RATING

Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Average Technical Analysis

5 day Moving Average is 7.94 And 5 day price change is 0.07 (0.89%)  with average volume for 5 day average is 1,892,080. While technical analysis for average 20 days shows significant difference, 20 day moving average is  7.43 and 20 day price change is 0.6 (0.0821) and average 20 day moving volume is 1,822,950. 50 day moving average is 7.01  and 50 day price change is 1.96 ( 0.3294)  and with average volume for 50 days is : 1,342,114. 200 day moving average is 5.72  and 200 day price change is 2.27 (40.25%)  and with average volume for 200 days is : 943,012.

See More Analyst Rating at: RATING

Corbus Pharmaceuticals Earnings and What to expect: 

Corbus Pharmaceuticals last issued its quarterly earnings data on May 11th, 2020. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.03. The firm earned $1.76 million during the quarter, compared to analysts’ expectations of $1.64 million. Corbus Pharmaceuticals has generated ($1.12) earnings per share over the last year. Corbus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 13th, 2020 based off prior year’s report dates.

Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($1.64) to ($1.51) per share. The P/E ratio of Corbus Pharmaceuticals is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Corbus Pharmaceuticals is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Corbus Pharmaceuticals has a P/B Ratio of 79.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 8.20%
  • On 3/17/2020 Insider Barbara White Buy 15,606 at average share price of $3.82 which equates to $59,614.92 in money value.
  • On 3/17/2020 COO Robert Paul Discordia Buy 2,840 at average price of  $3.82 with total value of : Not Data Available
  • On 11/12/2019 CEO Yuval Cohen Buy 1,430 at average price of  $4.26 with total value of : $6,091.80

What other brokers have to say about Corbus Pharmaceuticals :

  • 6/26/2020 – Corbus Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2020 – Corbus Pharmaceuticals had its “buy” rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $28.00 price target on the stock.
  • 6/17/2020 – Corbus Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/16/2020 – Corbus Pharmaceuticals is now covered by analysts at BTIG Research. They set a “buy” rating and a $22.00 price target on the stock.

Other firm’s rating by Oppenheimer Holdings Inc.:

  • 6/29/2020 – Global Payments had its price target raised by analysts at Oppenheimer Holdings Inc. from $190.00 to $202.00. They now have an “outperform” rating on the stock.
  • 6/29/2020 – Fidelity National Information Servcs had its price target raised by analysts at Oppenheimer Holdings Inc. from $145.00 to $161.00. They now have an “outperform” rating on the stock.
  • 6/29/2020 – Intercept Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating. They now have a $46.00 price target on the stock, down previously from $124.00.
  • 6/29/2020 – Kaleyra is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $12.00 price target on the stock.

See More Analyst Rating at: RATING